Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

A Multi-center Randomized Controlled Study of High/Low-dosage Rivaroxaban Compared With DAPT After Left Atrial Appendage Occulsion in Patients With Non-valvular Atrial Fibrillation(ESCORT-AF Study(B))

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT04135677
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-28T10:38:54.536039+00:00
Published At
2022-11-15T00:00:00+00:00
Record Updated At
2022-11-15
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Left Atrial Appendage Thrombosis", "Thrombi", "Stroke"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2022-11-15"
protocolSection.identificationModule.nctId
"NCT04135677"
protocolSection.identificationModule.officialTitle
"A Multi-center Randomized Controlled Study of High/Low-dosage Rivaroxaban Compared With DAPT After Left Atrial Appendage Occulsion in Patients With Non-valvular Atrial Fibrillation\uff08ESCORT-AF Study(B)\uff09"
protocolSection.statusModule.overallStatus
"UNKNOWN"
protocolSection.designModule.phases
["PHASE4"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
""

Study condition terms

  • Left Atrial Appendage Thrombosis (protocolSection.conditionsModule.conditions)
  • Thrombi (protocolSection.conditionsModule.conditions)
  • Stroke (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.